Features

How is innovation inspiring and fueling the transformation of the bio/pharma industry?DCAT’s conference and networking event, Expedition Pharma: Innovation from a Patient-First Perspective, being held June 4–5, 2025, in Lugano, Switzerland, will provide key insights.  

How do small-molecule drugs rank in the strategy of the bio/pharmaceutical majors? What are the leading products from a revenue perspective, and what are key developments on a commercial and pipeline basis? DCAT Value Chain Insights looks at what may be in store for 2025.

What are key issues shaping the market for bio/pharmaceutical outsourcing in the coming year? DCAT Value Chain Insights takes an inside look into the market drivers, trends, and key activity shaping the CDMO/CMO market.

Deal-making by the large pharma companies in antibody drug conjugates (ADCs) to build their in product portfolios in oncology has been on the upsurge, but will the ADC wave continue in 2025? A look at recent deals and what may lie ahead.

What are the key issues on the bio/pharma industry’s radar in 2025? DCAT Value Chain Insights weighs in on the key trends and developments shaping the industry in the year ahead: from manufacturing and supply lines to product innovation and new drug development.

How are bio/pharma companies and their partners collaborating to resolve the difficult challenges that arise in development, manufacturing, and the supply chain? DCAT Member Companies are invited to apply to share fresh insights, best practices, and lessons learned at a DCAT Week program. Applications close January 13, 2025.

As 2024 comes to a close, what were the key developments—expansions and M&A– from CDMOs/CMOs this year? DCAT Value Chain Insights looks at which companies topped the headlines this year and their moves.

Novo Holding’s pending $16.5-billion acquisition of Catalent was the deal of the year, driven by Novo’s interest to gain manufacturing capacity. But what pure-play bio/pharma M&A stood out?

As we begin to look back at 2024, what were the top developments from the bio/pharma industry this year? DCAT Value Chain Insights gives its take on the most significant news in the industry spanning manufacturing, product innovation, and deal-making.

The US government is rolling out a new initiative, the Cell and Gene Therapy Access Model, which uses a health outcomes payment model, with Vertex Pharmaceuticals and bluebird bio as the first manufacturers in the program. What’s the market impact?